Filing Flows › Boston Scientific (BSX) › Q2 2026
Boston Scientific (BSX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 3, 2026
Boston Scientific (BSX) reported revenue of $5.4B for the second quarter 2026 (Q2 2026), +8% from a year earlier and +5% from the quarter before. Operating margin was 21.6%, net earnings $905M (16.6% of revenue).
Boston Scientific, Q2 2026: revenue $5.4B (+8% year over year), operating margin 21.6%, net earnings $905M, operating cash flow $1.5B. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.4B | +5% | +8% |
| Gross profit | $3.8B | +6% | +12% |
| Operating profit | $1.2B | +7% | +44% |
| Net earnings | $905M | -32% | +14% |
| Operating cash flow | $1.5B | +324% | +15% |
| Free cash flow | $1.3B | +648% | +13% |
What changed
Revenue was $5.4B in Q2 2026, up 8% year over year and up 5% from the previous quarter. Interventional Cardiology & Vascular Therapies was the largest line at 24% of revenue. Interventional Cardiology & Vascular Therapies added $0.15B year over year (up 13%), 41% of the total change. Cardiac Rhythm Management declined 1%.
Gross margin was 70.7%, up 3.1 points from Q2 2025. Operating profit was $1.2B, a 21.6% margin (up 5.5 points year over year). Of the extra revenue versus Q2 2025, 94% reached operating profit, above the 16% margin then. Operating expenses grew 2% against revenue growth of 8%. Net earnings were $0.91B, up 14% year over year. The effective tax rate was 14.6%.
Operating cash flow was $1.5B (up 15% year over year), 163% of net earnings. Non-cash charges added back $0.35B of depreciation and amortization and $0.09B of share-based compensation. Working capital and other items added $0.13B. Capital expenditures of $0.20B left free cash flow of $1.3B.
Questions
What was Boston Scientific's revenue in the second quarter 2026?
Boston Scientific (BSX) reported revenue of $5.4B for the second quarter 2026 (Q2 2026), +8% from a year earlier and +5% from the quarter before.
Was Boston Scientific profitable in the second quarter 2026?
Operating profit was $1.2B (21.6% of revenue) and net earnings $905M.
Source: Boston Scientific 10-Q on SEC EDGAR.